HRP20150615T1 - Potpuno ljudska anti-vap-1 monoklonska protutijela - Google Patents
Potpuno ljudska anti-vap-1 monoklonska protutijela Download PDFInfo
- Publication number
- HRP20150615T1 HRP20150615T1 HRP20150615TT HRP20150615T HRP20150615T1 HR P20150615 T1 HRP20150615 T1 HR P20150615T1 HR P20150615T T HRP20150615T T HR P20150615TT HR P20150615 T HRP20150615 T HR P20150615T HR P20150615 T1 HRP20150615 T1 HR P20150615T1
- Authority
- HR
- Croatia
- Prior art keywords
- vap
- inflammatory
- antibody
- disease
- fully human
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 230000002757 inflammatory effect Effects 0.000 claims 5
- 101710132836 Membrane primary amine oxidase Proteins 0.000 claims 4
- 206010003246 arthritis Diseases 0.000 claims 4
- 208000018631 connective tissue disease Diseases 0.000 claims 4
- 102000056133 human AOC3 Human genes 0.000 claims 4
- 208000036487 Arthropathies Diseases 0.000 claims 3
- 206010048768 Dermatosis Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 201000002481 Myositis Diseases 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 208000017520 skin disease Diseases 0.000 claims 3
- 208000023328 Basedow disease Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 208000015023 Graves' disease Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000003603 inflammatory spondylopathy Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 206010043778 thyroiditis Diseases 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010003267 Arthritis reactive Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012441 Dermatitis bullous Diseases 0.000 claims 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 claims 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 206010015218 Erythema multiforme Diseases 0.000 claims 1
- 206010015943 Eye inflammation Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims 1
- 206010022941 Iridocyclitis Diseases 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000000185 Localized scleroderma Diseases 0.000 claims 1
- 206010027982 Morphoea Diseases 0.000 claims 1
- 208000022599 Papulosquamous Skin disease Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047124 Vasculitis necrotising Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000002353 alcoholic hepatitis Diseases 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 201000004612 anterior uveitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000010353 central nervous system vasculitis Diseases 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 201000004614 iritis Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 230000001185 psoriatic effect Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Claims (15)
1. Anti-VAP-1 protutijelo ili njegov vezni dio VAP-1, karakteriziran na način da je potpuno ljudski i sadrži polipeptid teškog lanca opisan slijedom identifikacijskog broja SEQ ID NO: 47 ili inačica njegovog nepromjenjivog slijeda, i polipeptid lakog lanca opisan u SEQ ID NO: 48 ili inačica njegovog nepromjenjivog slijeda;
pri čemu anti-VAP-1 protutijelo ili njegov vezni dio VAP-1 pokazuje poboljšani profil koncentracije u serumu tijekom vremena (AUC) i produljeno poluvrijeme eliminacije u odnosu na kimerično anti-VAP-1 protutijelo nazvano BTT-1002.
2. Protutijelo u skladu s patentnim zahtjevom 1, pri čemu je navedeni dio protutijela Fab, Fab', F(ab')2, Fv ili jednolančani Fv.
3. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 2, pri čemu je navedeno protutijelo rekombinantno protutijelo.
4. Ekspresijski vektor koji kodira protutijelo iz patentnog zahtjeva 1, sadrži slijed nukleinskih kiselina opisan u SEQ ID NO: 89, ili inačica njegovog nepromjenjivog slijeda, ili slijed nukleinskih kiselina opisan u SEQ ID NO: 90, ili inačica njegovog nepromjenjivog slijeda.
5. Stanica domaćin ili organizam različit od ljudskog koji sadrži ekspresijski vektor u skladu s patentnim zahtjevom 4.
6. Metoda za stvaranje potpuno ljudskog anti-VAP-1 protutijela, obuhvaća korake
a) transformiranja odgovarajuće stanice domaćina barem jednim ekspresijskim vektorom u skladu s patentnim zahtjevom 4,
b) kultiviranje navedenog domaćina pod uvjetima koji pogoduju ekspresiji, i
c) pročišćavanje dobivenih potpuno ljudskih protutijela iz medija za kultiviranje.
7. Potpuno ljudsko anti-VAP-1 protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 3 za uporabu kao lijek ili za in vivo uporabu kao dijagnostički agens.
8. In vitro dijagnostička metoda obuhvaća potpuno ljudsko anti-VAP-1 protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 3.
9. Uporaba potpuno ljudskog anti-VAP-1 protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 3 za proizvodnju farmaceutskog sastava za liječenje VAP-1 posredovanog upalnog poremećaja odabranog iz grupe koja se sastoji od artritisa i bolesti vezivnog tkiva, upalnih bolesti crijeva, dermatoze, multiple skleroze, upalne neuropatije, upalne miopatije, akutnog diseminiranog encefalomijelitisa, vaskulitisa središnjeg živčanog sustava, Sjögrenovog sindroma, dijabetesa, sustavnog eritemskog lupusa, astme, upalne bolesti jetre, Gravesove bolesti i tiroiditisa.
10. Farmaceutski sastav koji obuhvaća potpuno ljudsko anti-VAP-1 protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 3.
11. Farmaceutski sastav u skladu s patentnim zahtjevom 10 za liječenje ili dijagnostiku VAP-1 posredovanog upalnog poremećaja odabranog iz grupe koja se sastoji od artritisa i bolesti vezivnog tkiva, upalnih bolesti crijeva, dermatoze, multiple skleroze, upalne neuropatije, upalne miopatije, akutnog diseminiranog encefalomijelitisa, vaskulitisa središnjeg živčanog sustava, Sjögrenovog sindroma, dijabetesa, sustavnog eritemskog lupusa, astme, upalne bolesti jetre, Gravesove bolesti i tiroiditisa.
12. Farmaceutski sastav u skladu s patentnim zahtjevom 11, pri čemu su navedeni artritis i bolest vezivnog tkiva odabrani iz grupe koja se sastoji od reaktivnih artropatija, postinfektivnih artropatija, upalnih poliartropatija, sustavnih bolesti vezivnog tkiva, upalnih spondilopatija, miozitisa, sinovitisa, Reiterove bolesti, seropozitivnog reumatoidnog artritisa, reumatoidnog artritisa, ekstraartikularne reumatske bolesti, psorijatskih i enteropatskih artropatija, juvenilnog artritisa, artritisa, poliarteritisa nodoze i srodnih stanja, nekrotizirajućih vaskulopatija, dermatopolimiozitisa, sustavne skleroze, sustavnog zahvaćenja vezivnog tkiva, ankilozantnog spondilitisa i upalnih spondilopatija.
13. Farmaceutski sastav u skladu s patentnim zahtjevom 12, pri čemu je navedena upalna bolest crijeva odabrana iz grupe koja se sastoji od Chronove bolesti i ulceroznog kolitisa.
14. Farmaceutski sastav u skladu s patentnim zahtjevom 12, pri čemu je navedena dermatoza odabrana iz grupe koja se sastoji od buloznih poremećaja, dermatitisa, papuloskvamoznih poremećaja, eritema, atrofične lichen skleroze, krauroze vulve, diskoidnog eritemskog lupusa, morfeje, pemfigusa, pemfigoida, herpetiformnog dermatitisa, atopičnog dermatitisa, alergijskog kontaktnog dermatitisa, kontaktnog dermatitisa, psorijaze, multiformnog eritema.
15. Farmaceutski sastav u skladu s patentnim zahtjevom 12, pri čemu je navedena upalna bolest odabrana iz grupe koja se sastoji od ateroskleroze, upale oka uključujući uveitis, iritis, iridociklitis, alkoholnog hepatitisa, transplantacije alografta, transplantacije ksenografta, glomerulonefritisa, reperfuzijske ozljede i akutnih upalnih stanja nakon infarkta miokarda i moždanog udara.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90790407P | 2007-04-20 | 2007-04-20 | |
| FI20075278A FI20075278A0 (fi) | 2007-04-20 | 2007-04-20 | Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet |
| PCT/FI2008/050199 WO2008129124A1 (en) | 2007-04-20 | 2008-04-17 | Novel fully human anti-vap-1 monoclonal antibodies |
| EP08736848.6A EP2164872B1 (en) | 2007-04-20 | 2008-04-17 | Fully human anti-vap-1 monoclonal antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150615T1 true HRP20150615T1 (hr) | 2015-07-03 |
Family
ID=38009931
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150615TT HRP20150615T1 (hr) | 2007-04-20 | 2015-06-08 | Potpuno ljudska anti-vap-1 monoklonska protutijela |
| HRP20181616TT HRP20181616T1 (hr) | 2007-04-20 | 2018-10-05 | Potpuno ljudska anti-vap-1 monoklonska antitijela |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20181616TT HRP20181616T1 (hr) | 2007-04-20 | 2018-10-05 | Potpuno ljudska anti-vap-1 monoklonska antitijela |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7897149B2 (hr) |
| EP (2) | EP2692737B1 (hr) |
| JP (1) | JP5728225B2 (hr) |
| KR (1) | KR101352416B1 (hr) |
| CN (1) | CN101679523B (hr) |
| AU (1) | AU2008240560B2 (hr) |
| CA (5) | CA3059600C (hr) |
| CY (2) | CY1116413T1 (hr) |
| DK (2) | DK2164872T3 (hr) |
| ES (2) | ES2540566T3 (hr) |
| FI (1) | FI20075278A0 (hr) |
| HK (1) | HK1141039A1 (hr) |
| HR (2) | HRP20150615T1 (hr) |
| HU (1) | HUE041656T2 (hr) |
| IL (1) | IL201601A (hr) |
| LT (1) | LT2692737T (hr) |
| NZ (1) | NZ580194A (hr) |
| PL (2) | PL2692737T3 (hr) |
| PT (2) | PT2692737T (hr) |
| RS (1) | RS54066B1 (hr) |
| RU (1) | RU2459832C2 (hr) |
| SI (2) | SI2164872T1 (hr) |
| UA (1) | UA97516C2 (hr) |
| WO (1) | WO2008129124A1 (hr) |
| ZA (1) | ZA200907220B (hr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI20075278A0 (fi) * | 2007-04-20 | 2007-04-20 | Biotie Therapies Corp | Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet |
| MX2011010570A (es) | 2009-05-08 | 2011-10-19 | Genentech Inc | Anticuerpos anti-egfl7 humanizados y metodos de uso de los mismos. |
| UA112154C2 (uk) * | 2009-09-08 | 2016-08-10 | Біоті Терапіс Корп. | Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів |
| TWI594764B (zh) * | 2010-04-12 | 2017-08-11 | 生化治療公司 | 治療用途 |
| ES2702246T3 (es) * | 2012-03-26 | 2019-02-28 | Sanofi Sa | Formulaciones de agente de unión IgG4 estables |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| ES2702183T3 (es) * | 2013-03-15 | 2019-02-27 | Mayo Found Medical Education & Res | Identificación y monitorización de inmunoglobulinas monoclonales por masa molecular |
| WO2014199171A1 (en) | 2013-06-12 | 2014-12-18 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| BR112016023046A8 (pt) | 2014-04-04 | 2021-05-11 | Mayo Found Medical Education & Res | kit compreendendo anticorpos e agentes redutores |
| WO2015189534A1 (en) | 2014-06-12 | 2015-12-17 | Proximagen Limited | Vap-1 inhibitors for treating muscular dystrophy |
| US10690676B2 (en) | 2014-07-29 | 2020-06-23 | Mayo Roundation for Medical Education and Research | Quantifying monoclonal antibody therapeutics by LC-MS/MS |
| CN104628853B (zh) * | 2015-02-06 | 2017-10-10 | 中国人民解放军南京军区军事医学研究所 | 人源抗炭疽保护性抗原PA的抗体IgG及其应用 |
| JP6968058B2 (ja) | 2015-09-24 | 2021-11-17 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | 質量分析法による免疫グロブリン遊離軽鎖の同定 |
| AU2016366635A1 (en) | 2015-12-07 | 2018-06-21 | Benevolentai Cambridge Limited | VAP-1 inhibitors for treating pain |
| EP3455371B1 (en) | 2016-05-09 | 2023-01-18 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Tissue-specific exosomes as biomarkers |
| EP3523647B1 (en) | 2016-09-07 | 2024-06-26 | Mayo Foundation for Medical Education and Research | Identification and monitoring of cleaved immunoglobulins by molecular mass |
| US11427634B2 (en) * | 2017-05-05 | 2022-08-30 | Vaccinex, Inc. | Human anti-semaphorin 4D antibody |
| US11946937B2 (en) | 2017-09-13 | 2024-04-02 | Mayo Foundation For Medical Education And Research | Identification and monitoring of apoptosis inhibitor of macrophage |
| CA3079568A1 (en) * | 2017-10-18 | 2019-04-25 | Regenxbio Inc. | Fully-human post-translationally modified antibody therapeutics |
| CN111537740B (zh) * | 2020-05-22 | 2021-11-23 | 长春生物制品研究所有限责任公司 | 一种森林脑炎病毒IgM抗体检测试剂盒及其应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5580780A (en) * | 1992-06-09 | 1996-12-03 | Jalkanen; Sirpa | Vascular adhesion protein-(VAP-1) and VAP-1-specific antibodies |
| ATE184315T1 (de) * | 1992-06-09 | 1999-09-15 | Biotie Therapies Oy | Neuartiges endothelzell-molekül, das die bindung von lymphozyten im menschen vermittelt |
| CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| CN1269829A (zh) * | 1997-05-23 | 2000-10-11 | 拜奥泰治疗有限公司 | 有胺氧化酶活性的血管粘着蛋白－1 |
| US6984720B1 (en) | 1999-08-24 | 2006-01-10 | Medarex, Inc. | Human CTLA-4 antibodies |
| CA2481334A1 (en) * | 2002-04-01 | 2003-10-16 | Anthony C. Stevens | Tissue-specific endothelial membrane proteins |
| FI20020807A0 (fi) * | 2002-04-29 | 2002-04-29 | Biotie Therapies Oyj | Uusia humanisoituja anti-VAP-1 monoklonaalisia vasta-aineita |
| FI20075278A0 (fi) | 2007-04-20 | 2007-04-20 | Biotie Therapies Corp | Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet |
-
2007
- 2007-04-20 FI FI20075278A patent/FI20075278A0/fi unknown
-
2008
- 2008-04-17 SI SI200831444T patent/SI2164872T1/sl unknown
- 2008-04-17 PL PL13190488T patent/PL2692737T3/pl unknown
- 2008-04-17 CN CN2008800209043A patent/CN101679523B/zh not_active Expired - Fee Related
- 2008-04-17 JP JP2010503537A patent/JP5728225B2/ja not_active Expired - Fee Related
- 2008-04-17 RS RS20150427A patent/RS54066B1/en unknown
- 2008-04-17 DK DK08736848.6T patent/DK2164872T3/en active
- 2008-04-17 UA UAA200910613A patent/UA97516C2/ru unknown
- 2008-04-17 HU HUE13190488A patent/HUE041656T2/hu unknown
- 2008-04-17 ES ES08736848.6T patent/ES2540566T3/es active Active
- 2008-04-17 PT PT13190488T patent/PT2692737T/pt unknown
- 2008-04-17 PL PL08736848T patent/PL2164872T3/pl unknown
- 2008-04-17 ES ES13190488.0T patent/ES2690307T3/es active Active
- 2008-04-17 EP EP13190488.0A patent/EP2692737B1/en active Active
- 2008-04-17 DK DK13190488.0T patent/DK2692737T3/en active
- 2008-04-17 SI SI200832000T patent/SI2692737T1/sl unknown
- 2008-04-17 CA CA3059600A patent/CA3059600C/en active Active
- 2008-04-17 WO PCT/FI2008/050199 patent/WO2008129124A1/en active Application Filing
- 2008-04-17 CA CA2962519A patent/CA2962519C/en active Active
- 2008-04-17 RU RU2009142808/10A patent/RU2459832C2/ru active
- 2008-04-17 AU AU2008240560A patent/AU2008240560B2/en not_active Ceased
- 2008-04-17 CA CA3059580A patent/CA3059580C/en active Active
- 2008-04-17 LT LTEP13190488.0T patent/LT2692737T/lt unknown
- 2008-04-17 CA CA2683079A patent/CA2683079C/en active Active
- 2008-04-17 CA CA3059571A patent/CA3059571C/en active Active
- 2008-04-17 PT PT87368486T patent/PT2164872E/pt unknown
- 2008-04-17 EP EP08736848.6A patent/EP2164872B1/en active Active
- 2008-04-17 NZ NZ580194A patent/NZ580194A/en not_active IP Right Cessation
- 2008-04-17 KR KR1020097021869A patent/KR101352416B1/ko active IP Right Grant
- 2008-04-18 US US12/081,707 patent/US7897149B2/en not_active Expired - Fee Related
-
2009
- 2009-10-15 ZA ZA200907220A patent/ZA200907220B/xx unknown
- 2009-10-18 IL IL201601A patent/IL201601A/en active IP Right Grant
-
2010
- 2010-08-09 HK HK10107584.5A patent/HK1141039A1/xx not_active IP Right Cessation
- 2010-11-05 US US12/940,476 patent/US8142783B2/en not_active Expired - Fee Related
-
2015
- 2015-06-08 HR HRP20150615TT patent/HRP20150615T1/hr unknown
- 2015-06-23 CY CY20151100533T patent/CY1116413T1/el unknown
-
2018
- 2018-10-05 HR HRP20181616TT patent/HRP20181616T1/hr unknown
- 2018-10-05 CY CY181101032T patent/CY1121132T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150615T1 (hr) | Potpuno ljudska anti-vap-1 monoklonska protutijela | |
| HRP20191704T1 (hr) | Multispecifična protutijela | |
| ES2965032T3 (es) | Fabricación de proteínas | |
| HRP20191835T1 (hr) | Protutijela anti-il-36r | |
| JP2013063981A5 (hr) | ||
| HRP20150776T1 (hr) | Humanizirana protutijela koja su specifiäśna za protofibrilarni oblik beta-amiloidnog peptida | |
| HRP20192076T1 (hr) | Anti-il-17a protutijela i njihova uporaba u liječenju autoimunih i upalnih poremećaja | |
| HRP20200174T1 (hr) | Antitijela antigena 2 anti-krvne dendritične stanice i njihova uporaba | |
| RU2017105120A (ru) | Cd3-связывающий домен | |
| JP2011083291A5 (hr) | ||
| CY1110939T1 (el) | Μεθοδος κατασκευης μιας ανασυνδυασμενης πολυκλωνης πρωτεινης | |
| JP2017163973A5 (hr) | ||
| HRP20201633T1 (hr) | Protutijela koja se vežu na il-23 | |
| JP2011526785A5 (hr) | ||
| RU2487723C2 (ru) | Химерные и гуманизированные антитела к cd44, которые опосредствуют цитотоксичность в отношении раковых клеток | |
| JP2010273685A5 (hr) | ||
| HRP20160638T1 (hr) | Antigen vezujući proteini sposobni vezati timusni stromalni limfopoetin | |
| MX2007013031A (es) | Agentes terapeuticos de peptidos de toxina. | |
| RU2010135624A (ru) | Стабилизированные антитела против ангиопоэтина-2 и их применение | |
| JP2012100667A5 (hr) | ||
| RU2013153592A (ru) | Анти-mif антитела | |
| AR073978A1 (es) | Anticuerpos humanos de alta afinidad para el receptor il-4-humano | |
| HRP20210120T1 (hr) | Protutijela protiv tnf alfa i njihovi funkcionalni fragmenti | |
| EA201692359A1 (ru) | Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса | |
| JP2015514423A5 (hr) |